So, whatever happened to swine flu?

As stories unfold about piles of unused and nearly out-of-date H1N1 “swine flu” vaccinations, I was interested to come across the Council of Europe’s parliamentary assembly ‘s enquiry into the “pandemic”  – WHO challenged at public hearing on the handling of the Swine Flu pandemic.  

I’m glad to see that some of the concerns I’d written about a few months back – the new definition of “pandemic” being one of them – being brought to light. The conclusions will be published and debated later this year.

My endeavour to find a trial of vaccination against placebo to which I or my under-5 year old could be entered has drawn a blank. As to why it’s important, this commentary -  Why the MRC randomized trials of whooping cough (pertussis) vaccines remain important more than half a century after they were done – from the James Lind Library is about trials for whooping cough vaccine.

Note – immune response from vaccines was independant of clinical response. “i) it is difficult to forecast the field performance of any whole-cell pertussis vaccine without randomized placebo controlled trials using clinical outcome measures; and (ii) it is impossible to extrapolate from the result of an assessment of one type of whole-cell vaccine to reliable assessments of the effects of another vaccine.”

Health and science blog




This blog, part of the FT's health series, is a forum for readers interested in the science, policy, management, technology, business and delivery of healthcare.

This blog is no longer active but it remains open as an archive.
Follow on twitter

About our regular bloggers

Margaret McCartney is a Glasgow-based GP and FT Weekend columnist. She started writing for the Life and Arts section in 2005 and moved to the magazine in 2008. She also has her own blog: www.margaretmccartney.com/blog

Clive Cookson has been a science journalist for the whole of his working life. He joined the FT in 1987. Clive, the FT's science editor, picks out the research that everyone should know about. He also discusses key policy issues, from R&D funding to science education.

Andrew Jack is pharmaceuticals correspondent, covering the industry and public health issues. He has been a journalist with the FT for 19 years, based in London, Paris and Moscow

The Health blog: a guide

Comment: To comment, please register with FT.com, which you can do for free here. Please also read our comments policy here.
Contact: You can write to Ursula Milton, the blog's editor, using this email format: firstname.surname@ft.com
Time: UK time is shown on posts.
Follow: Links to the blog's Twitter and RSS feeds are at the top of the page. You can also read the Health blog on your mobile device, by going to www.ft.com/healthblog
FT blogs: See the full range of the FT's blogs here.